Recently, it has been shown that carriers of monoallelic loss of function MUTYH germline variants are at a higher risk of developing cancer, especially in tumors with frequent loss of heterozygosity events, such as adrenal adenocarcinoma, although the overall risk is still low (Barreiro et al., 2022); unfortunately, tumor sample of Patient P28, who carry a germline heterozygous MUTYH variant, was not available to check if loss of heterozygosity was present as a second hit, as suggested by authors. This evidence concerns the gene MUTYH and neoplasm.